Pfizer has initiated the process of identifying a successor to Dr. Mikael Dolsten, who will depart the company after a distinguished 15-year tenure as Chief Scientific Officer and President of Pfizer Research and Development. "After more than 15 years as the architect of Pfizer’s exceptional scientific and research and development resurgence, Mikael and I recently discussed starting the process to look for his successor," stated Albert Bourla, Chairman and Chief Executive Officer of Pfizer. The approval of over 35 drugs and vaccines, of which over half were novel molecular entities, has been a defining feature of Dr. Dolsten's tenure at Pfizer. He has made significant contributions to a variety of therapeutic areas, such as inflammation, cardiovascular health, stroke prevention, cancer, and hemophilia.
Notably, he was instrumental in the development and approval of Pfizer's COVID-19 vaccine and oral therapeutic. In 2009, Dr. Dolsten became the President of Worldwide Research and Development at Pfizer, following the Wyeth acquisition. He was responsible for the company's research and development endeavors through Phase 2 trials. Maintaining a dedication to the quality, safety, and value of healthcare products such as vaccines and medications, Pfizer continues to capitalize on its global resources and scientific expertise to provide innovative therapies that enhance and prolong life.
